๐”– Bobbio Scriptorium
โœฆ   LIBER   โœฆ

Selegiline, fluoxetine, and depression in Parkinson's disease

โœ Scribed by Juan Carlos Garcia-Monco; Angel Padierna; Marian Gomez Beldarrain


Publisher
John Wiley and Sons
Year
1995
Tongue
English
Weight
134 KB
Volume
10
Category
Article
ISSN
0885-3185

No coin nor oath required. For personal study only.


๐Ÿ“œ SIMILAR VOLUMES


Selegiline and mortality in Parkinson's
โœ Dr. C. W. Olanow; S. Fahn; J. W. Langston; J. Godbold ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 489 KB ๐Ÿ‘ 2 views

## Do Other Studies Show Increased Mortality Due to Selegiline? Other than the UK study, no clinical trial to date has shown an increase in mortality in association with the use of selegiline. In the Sindepar study, a cohort of I01 untreated P D patients participated in a 14-month prospective, ran

Fluoxetine in Parkinson's disease
โœ J. A. Simons ๐Ÿ“‚ Article ๐Ÿ“… 1996 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 237 KB
Subthreshold depression in Parkinson's d
โœ Daniel A. Nation; Heather L. Katzen; Spyridon Papapetropoulos; Blake K. Scanlon; ๐Ÿ“‚ Article ๐Ÿ“… 2009 ๐Ÿ› John Wiley and Sons ๐ŸŒ English โš– 86 KB ๐Ÿ‘ 2 views

## Abstract ## Objective It is estimated that 40% of patients with Parkinson's disease (PD) are clinically depressed, however, little is known about the frequency and associated features of subthreshold depression in PD. The current study sought to determine the prevalence of subthreshold depressi